Search Within

Alison Moskowitz

Formats
  1. Meeting Abstract (197)
  2. Journal Article (126)
  3. Review (13)
  4. Research Letter (12)
  5. Editorial (5)
  6. Guidelines (4)
  7. Correspondence (2)
  8. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (360)
  2. Department of Medicine (360)
  3. Hematologic Malignancies, Division of (360)
  4. Lymphoma (360)
  5. Population Sciences Research Program (235)
  6. Hematology-Oncology Fellows (164)

More Groups

People
  1. Steven Horwitz (234)
  2. Andrew Zelenetz (130)
  3. Paul Hamlin (119)
  4. Ariela Noy (118)
  5. Anita Kumar (106)
  6. Maria Palomba (103)

More People

Years
  1. 2025 (12)
  2. 2024 (37)
  3. 2023 (37)
  4. 2022 (20)
  5. 2021 (36)
  6. 2020 (30)

More Years

Publications
  1. Blood (150)
  2. Hematological Oncology (23)
  3. Journal of Clinical Oncology (22)
  4. Blood Advances (15)
  5. Journal of the American Academy of Dermatology (15)
  6. Leukemia and Lymphoma (15)

More Publications

Publishers
  1. American Society of Hematology (168)
  2. Wiley Blackwell (31)
  3. American Society of Clinical Oncology (25)
  4. Elsevier Inc. (22)
  5. Taylor & Francis Group (16)
  6. Mosby Elsevier (15)

More Publishers

Results (360)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma
    Journal Article

    Lahoud, O. B.; Moskowitz, A. J.; Horwitz, S. M.; Giralt, S. A.; Dahi, P. B.
    Bone Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • ALK-positive primary cutaneous anaplastic large cell lymphoma: A case report and review of the literature
    Journal Article

    Geller, S.; Canavan, T. N.; Pulitzer, M.; Moskowitz, A. J.; Myskowski, P. L.
    International Journal of Dermatology (2018)

    Fulltext@MSK | Save
  • Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
    Journal Article

    Horwitz, S. M.; Koch, R.; Porcu, P.; Oki, Y.; Moskowitz, A.; Perez, M.; Myskowski, P.; Officer, A.; Jaffe, J. D.; Morrow, S. N.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • The optimal regimen of brentuximab vedotin for CD30(+) cutaneous lymphoma: Are we there yet?
    Journal Article

    Geller, S.; Myskowski, P. L.; Kim, Y. H.; Moskowitz, A.; Horwitz, S.
    British Journal of Dermatology (2018)

    Fulltext@MSK | Save
  • Early toxicities associated with radiation based conditioning for relapsed/refractory Hodgkin lymphoma patients undergoing high dose therapy and autologous stem cell transplantation (HDT-ASCT)
    Meeting Abstract

    Shah, G. L.; Scordo, M.; Devlin, S. M.; Yahalom, J.; Matasar, M. J.; Moskowitz, A.; Giralt, S. A.; Moskowitz, C. H.
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Measurement of PD-1 expression on lymphoma cells by flow cytometry is a useful tool in diagnosing and monitoring minimal residual disease in angioimmunoblastic T-cell lymphoma
    Meeting Abstract

    Yabe, M.; Ozkaya, N.; Gao, Q.; Pichardo, J.; Huet, S.; Moskowitz, A. J.; Horwitz, S. M.; Dogan, A.; Roshal, M.
    Blood (2017)

    Fulltext@MSK | Save
  • Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: The largest multicenter retrospective analysis
    Meeting Abstract

    Mehta-Shah, N.; Teja, S.; Tao, Y.; Cashen, A. F.; Beaven, A.; Alpdogan, O.; Porcu, P.; Wiggin, M.; Song, K. W.; Alzahrani, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): Results from the phase III MAVORIC study
    Meeting Abstract

    Kim, Y. H.; Bagot, M.; Pinter-Brown, L.; Rook, A. H.; Porcu, P.; Horwitz, S. M.; Whittaker, S.; Tokura, Y.; Vermeer, M.; Zinzani, P. L.; more...
    Blood (2017)

    Fulltext@MSK | Save